Last 34 quarters of trend data · Healthcare · Rare Disease Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -12.24 | — | — | — | — | — | — | — | — | — | — | — | — | 178.54 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 6.73 | 7.83 | 7.81 | 6.05 | 4.97 | 5.22 | 3.80 | 3.87 | 3.37 | 3.05 | 3.46 | 3.82 | 5.58 | 3.01 | 2.11 | 2.55 | 1.40 | 3.89 | 3.15 | 2.33 | 2.73 |
| — | +49.9% | +105.5% | +56.3% | +47.4% | +71.3% | +9.7% | +1.4% | -39.5% | +1.2% | +64.0% | +49.8% | +298.4% | -22.7% | -33.0% | +9.6% | -48.7% | +40.2% | -3.3% | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | 3.67 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -65.2% | -17.8% | -15.7% | -16.0% | -15.0% | -22.2% | -18.8% | -13.1% | -13.3% | -8.6% | -7.5% | -13.1% | -14.4% | -15.7% | -17.4% | -23.9% | -4.5% | -7.0% | -8.1% | -5.9% | -4.2% |
| — | +19.8% | +16.5% | -22.0% | -12.9% | -158.4% | -149.3% | -0.2% | +8.2% | +45.4% | +56.8% | +45.2% | -217.5% | -123.5% | -115.4% | -307.2% | -8.8% | -6.0% | -122.0% | +62.6% | +79.6% | |
| ROA | -59.3% | -16.3% | -14.2% | -14.6% | -13.5% | -19.9% | -17.2% | -12.3% | -12.5% | -8.2% | -7.2% | -12.4% | -13.1% | -14.1% | -15.4% | -21.6% | -4.2% | -6.6% | -7.8% | -5.7% | -4.0% |
| — | +18.1% | +17.4% | -19.0% | -7.9% | -143.7% | -138.0% | +1.1% | +4.6% | +42.3% | +53.1% | +42.5% | -215.1% | -114.4% | -98.4% | -280.3% | -3.3% | -2.6% | -121.5% | +61.3% | +78.4% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | -34.9% | -4.9% | -11.0% | +370.3% | +715.2% | +520.4% | +417.2% | -79.3% | -78.3% | -82.3% | -78.7% | +77.2% | +74.4% | +154.7% | +139.7% | -15.6% | -13.2% | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | 0.02 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 10.11 | 11.94 | 11.24 | 10.11 | 12.86 | 8.33 | 11.10 | 12.60 | 19.08 | 18.45 | 20.53 | 27.25 | 10.46 | 11.89 | 7.96 | 9.16 | 11.43 | 12.85 | 19.84 | 30.28 | 29.71 |
| — | +43.4% | +1.3% | -19.8% | -32.6% | -54.9% | -45.9% | -53.8% | +82.4% | +55.2% | +158.0% | +197.6% | -8.5% | -7.5% | -59.9% | -69.8% | -61.5% | -59.1% | -31.3% | +59.4% | +201.4% | |
| Quick Ratio | 10.11 | 11.94 | 11.24 | 10.11 | 12.86 | 8.33 | 11.10 | 12.60 | 19.08 | 18.45 | 20.53 | 27.25 | 10.46 | 11.35 | 7.37 | 8.93 | 11.43 | 12.85 | 19.84 | 30.28 | 29.26 |
| — | +43.4% | +1.3% | -19.8% | -32.6% | -54.9% | -45.9% | -53.8% | +82.4% | +62.5% | +178.6% | +205.0% | -8.5% | -11.7% | -62.9% | -70.5% | -60.9% | -58.3% | -31.3% | +59.4% | +196.9% | |
| Interest Coverage | — | — | -449.54 | — | — | — | — | — | -4539.85 | — | — | -5871.63 | -5268.10 | -1358.41 | -4246.33 | — | -417.22 | -313.21 | -430.08 | — | -190.95 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 34 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PHVS stock.
Pharvaris N.V.'s current P/E is -12.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Pharvaris N.V.'s business trajectory between earnings reports.